Beijing Beilu Pharmaceutical (300016) — Net Asset Quality Index
Beijing Beilu Pharmaceutical (300016) has a Net Asset Quality Index of 73.5% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.22 Billion minus total liabilities of CN¥852.80 Million yields net assets of CN¥2.37 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300016 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing Beilu Pharmaceutical Net Asset Quality Index Over Time (2005–2024)
This chart shows how Beijing Beilu Pharmaceutical's Net Asset Quality Index has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the index stands at 73.5%, representing net assets of CN¥2.37 Billion against total assets of CN¥3.22 Billion CNY. See Beijing Beilu Pharmaceutical current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Beijing Beilu Pharmaceutical (2005–2024)
The table below presents the year-by-year Net Asset Quality Index for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Beijing Beilu Pharmaceutical market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 61.4% | CN¥1.83 Billion | CN¥2.98 Billion | CN¥1.15 Billion | ▼ -1.9 pp |
| 2023 | 63.4% | CN¥1.79 Billion | CN¥2.82 Billion | CN¥1.03 Billion | ▼ -5.0 pp |
| 2022 | 68.3% | CN¥1.92 Billion | CN¥2.82 Billion | CN¥892.27 Million | ▼ -3.5 pp |
| 2021 | 71.8% | CN¥2.08 Billion | CN¥2.90 Billion | CN¥818.22 Million | ▲ +5.4 pp |
| 2020 | 66.4% | CN¥1.89 Billion | CN¥2.85 Billion | CN¥955.50 Million | ▼ -22.9 pp |
| 2019 | 89.3% | CN¥1.45 Billion | CN¥1.62 Billion | CN¥173.31 Million | ▼ -4.2 pp |
| 2018 | 93.6% | CN¥1.21 Billion | CN¥1.29 Billion | CN¥82.93 Million | ▼ -0.2 pp |
| 2017 | 93.7% | CN¥1.07 Billion | CN¥1.14 Billion | CN¥71.65 Million | ▼ -0.6 pp |
| 2016 | 94.3% | CN¥901.69 Million | CN¥956.09 Million | CN¥54.40 Million | ▲ +5.5 pp |
| 2015 | 88.8% | CN¥932.63 Million | CN¥1.05 Billion | CN¥117.39 Million | ▲ +15.4 pp |
| 2014 | 73.5% | CN¥666.33 Million | CN¥907.00 Million | CN¥240.67 Million | ▼ -16.7 pp |
| 2013 | 90.1% | CN¥559.38 Million | CN¥620.54 Million | CN¥61.16 Million | ▲ +0.4 pp |
| 2012 | 89.8% | CN¥523.96 Million | CN¥583.60 Million | CN¥59.64 Million | ▼ -3.9 pp |
| 2011 | 93.7% | CN¥491.47 Million | CN¥524.66 Million | CN¥33.19 Million | ▼ -4.7 pp |
| 2010 | 98.4% | CN¥467.62 Million | CN¥475.11 Million | CN¥7.49 Million | ▲ +2.3 pp |
| 2009 | 96.1% | CN¥433.71 Million | CN¥451.31 Million | CN¥17.60 Million | ▲ +12.7 pp |
| 2008 | 83.4% | CN¥133.23 Million | CN¥159.75 Million | CN¥26.52 Million | ▲ +19.6 pp |
| 2007 | 63.8% | CN¥90.33 Million | CN¥141.69 Million | CN¥51.36 Million | ▲ +6.8 pp |
| 2006 | 57.0% | CN¥71.59 Million | CN¥125.69 Million | CN¥54.10 Million | ▼ -3.3 pp |
| 2005 | 60.2% | CN¥64.71 Million | CN¥107.46 Million | CN¥42.75 Million | — |